Here are the results of some of the trials we have been involved with, please click on the links below.
Some of these trials were of world-wide importance, and may not have been so successful if it were not for the hundreds of patients who took part.
Study Title: A randomised, double-blind, placebo-controlled Phase II study, comparing the efficacy and safety of inhaled SNG001 to placebo administered to asthmatic subjects after the onset of a respiratory viral infection for the prevention or attenuation of asthma symptoms caused by respiratory viruses. Company: Synairgen Research Ltd
ClinicalTrials.gov Identifier: NCT01126177
https://clinicaltrials.gov/ct2/show/NCT01126177?term=SNG001&rank=1Publication: Djukanović R, Harrison T, Johnston SL, Gabbay F, Wark P, Thomson NC, Niven R, Singh D, Reddel HK, Davies DE, Marsden R, Boxall C, Dudley S, Plagnol V, Holgate ST, Monk P; INTERCIA Study Group. The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial. Am J Respir Crit Care Med. 2014 Jul 15;190(2):145-54. doi: 10.1164/rccm.201312-2235OC.
http://www.ncbi.nlm.nih.gov/pubmed/24937476?dopt=Abstract
Study Title: MEA115575: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Mepolizumab Adjunctive Therapy to Reduce Steroid Use in Subjects with Severe Refractory Asthma XNxvdDxuQ7Ju6c9cX-3LBNLz6YqSg45FgFV-g095d-3Ws8Gpw-PSB7gW." title="Djukanović R, Harrison T, Johnston SL, Gabbay F, Wark P, Thomson NC, Niven R, Singh D, Reddel HK, Davies DE, Marsden R, Boxall C, Dudley S, Plagnol V, Holgate ST, Monk P; INTERCIA Study Group. The effect of inhaled IFN-β on worsening of asthma symptoms ca">Djukanović R, Harrison T, Johnston SL, Gabbay F, Wark P, Thomson NC, Niven R, Singh D, Reddel HK, Davies DE, Marsden R, Boxall C, Dudley S, Plagnol V, Holgate ST, Monk P; INTERCIA Study Group. The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial. Am J Respir Crit Care Med. 2014 Jul 15;190(2):145-54. doi: 10.1164/rccm.201312-2235OC.
Company: GSK
ClinicalTrials.gov Identifier: NCT01691508
https://clinicaltrials.gov/ct2/show/NCT01691508?term=MEA115575&rank=2 Publication: Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID; SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014 Sep 25;371(13):1189-97. doi: 10.1056/NEJMoa1403291. Epub 2014 Sep 8.
http://www.ncbi.nlm.nih.gov/pubmed/25199060?dopt=Abstract
http://www.gsk.com/en-gb/media/press-releases/2014/new-england-journal-of-medicine-and-ers-publish-positive-results-from-gsk-phase-iii-studies-of-mepolizumab-in-patients-with-severe-eosinophilic-asthma/
Study Title: MEA115661: A Multi-centre, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in the MEA115588 or MEA115575 Trials rials.gov/ct2/bye/xQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cX-3LBNLz6YqSgCjxKCtcR495d-3Ws8Gpw-PSB7gW." title="Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID; SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014 Sep 25;371(13):1189-97. doi: 10.1056/NEJMoa1403291. Ep">Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID; SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014 Sep 25;371(13):1189-97. doi: 10.1056/NEJMoa1403291. Epub 2014 Sep 8.
Company: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01842607
https://clinicaltrials.gov/ct2/show/NCT01842607
Study Title: A 16-week, randomized, placebo-controlled, double blind, and parallel group trial to
assess the anti-inflammatory effects of Roflumilast in chronic obstructive pulmonary
disease https://clinicaltrials.gov/ct2/show/NCT01842607
Company: TakedaPharma CT01842607
ClinicalTrials.gov Identifier: NCT01509677
https://clinicaltrials.gov/ct2/show/NCT01509677?term=anti-inflammatory+effects+of+Roflumilast&rank=1
Study Title: A Phase 2a, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI-563 in Subjects With Moderate-to-severe COPD and Sputum Eosinophilia
https://clinicaltrials.gov/ct2/show/NCT01509677?term=anti-inflammatory+effects+of+Roflumilast&rank=1
Company: MedImmune
ClinicalTrials.gov Identifer: NCT01227278
https://clinicaltrials.gov/ct2/show/NCT01227278?term=Medi+563&rank=5
Study Title: A Phase III Multicenter, Randomized, Parallel Group, Controlled, Double Blind Study to Investigate the Safety and Efficacy of Inhaled Mannitol Over 12 Months in the Treatment of Bronchiectasis.
https://clinicaltrials.gov/ct2/show/NCT01227278?term=Medi+563&rank=5
Company: Pharmaxis
ClinicalTrials.gov Identifier: NCT00669331
https://clinicaltrials.gov/ct2/show/NCT00669331
Publication: Daviskas E, Anderson SD, Eberl S, Chan HK, Bautovich G. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med. 1999 Jun;159(6):1843-8.
http://www.ncbi.nlm.nih.gov/pubmed/10351929?dopt=Abstract
